Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2018 | iFCG for IGHV-mutated CLL in the frontline

Susan O’Brien, MD, of the University of California, Irvine, CA, provides an overview of the Phase II trial (NCT02629809) assessing the combination of ibrutinib, fludarabine, cyclophosphamide and obinutuzumab (iFCG) as a frontline therapy for patients with IGHV-mutated chronic lymphocytic leukemia (CLL) vs. the current standard of care, FCR chemoimmunotherapy. Speaking from the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA, Prof. O’Brien discusses the increased efficacy of this combination, allowing short-duration chemotherapy and minimizing potential toxicities, and also reveals the higher rates of undetectable MRD with the iFCG regimen.